Healthcare
OS Therapies Incorporated(OSTX)
Live Price
Offline$1.82
-5.70% today
1Y Change
+3.41%
Window
Jun 25, 2025 โ Jun 23, 2026
- Market Cap
- $70.00M
- Revenue Growth
- 0.0%
- EPS Growth
- -88.5%
- Dividend Yield
- 0.0%
Coverage: 235 bars ยท Jun 25, 2025 โ Jun 23, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
OS Therapies Incorporated (OSTX) is a Healthcare stock with a market cap of $70.00M and listed on AMEX. The stock last traded around $1.82 and up 3.4% across the available one-year price window (Jun 25, 2025 โ Jun 23, 2026). Baseline metrics include revenue growth of 0.0%, EPS growth of -88.5%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS -88.5%, free cash flow -195423.2% with operating margin 0.0% and ROIC 582.9%. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines OSTX price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
0.0% vs +7.6% peer median
Operating Margin
Below sector median
0.0% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 21, 2026, but the surprise data is still limited.
The operating picture looks softer than before
Revenue is at 0.0% and EPS is at -88.5%, with operating margin around 0.0%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged -4.9% over the next 5 trading days and finished higher after 1 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 21, 2026 | โ | -2.9% | +1.7% | โ |
2026 Mar 31, 2026 | -201.5% | -3.5% | -11.3% | +15.6% |
2025 Nov 14, 2025 | -31.3% | -5.0% | -5.0% | -7.2% |
Benchmark Edge
OSTX vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
OSTX
โ
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
OSTX Max Drawdown
-53.60%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for OSTX and SPY.
Company Overview
OS Therapies Incorporated
New York Stock Exchange American
OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. Its pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers. OS Therapies Incorporated was incorporated in 2018 and is based in Rockville, Maryland.
- Leadership
- Paul A. Romness
- IPO Date
- Aug 1, 2024
- Employees
- 4
- Street Address
- 115 Pullman Crossing Road
- Mailing
- Rockville, MD, 21638
- Region
- Rockville, MD, US
- Reporting Currency
- USD
- Investor Line
- 410-297-7793
- Last Updated
- May 3, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- 7.1
- Price/Sales
- โ
- Price/Book
- โ
Growth
- Revenue
- 0.0%
- EPS
- -88.5%
- Free Cash Flow
- -195423.2%
Profitability
- Gross Margin
- 0.0%
- Operating Margin
- 0.0%
- Net Margin
- 0.0%
- ROE
- -1923.9%
- ROIC
- 582.9%
Balance Sheet
- Debt/Equity
- โ
- Current Ratio
- 0.03
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.